News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
345,978 Results
Type
Article (21114)
Company Profile (141)
Press Release (324709)
Multimedia
Podcasts (113)
Webinars (17)
Section
Business (105930)
Career Advice (892)
Deals (18669)
Drug Delivery (110)
Drug Development (51068)
Employer Resources (80)
FDA (7857)
Job Trends (7829)
News (186992)
Policy (17480)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (739)
Accelerated approval (20)
Adcomms (23)
Allergies (86)
Alliances (27970)
ALS (90)
Alzheimer's disease (792)
Antibody-drug conjugate (ADC) (209)
Approvals (8034)
Artificial intelligence (285)
Autoimmune disease (87)
Automation (16)
Bankruptcy (178)
Best Places to Work (5554)
BIOSECURE Act (14)
Biosimilars (172)
Biotechnology (60)
Bladder cancer (74)
Brain cancer (34)
Breast cancer (266)
Cancer (2329)
Cardiovascular disease (242)
Career advice (741)
Career pathing (25)
CAR-T (112)
CDC (14)
Cell therapy (295)
Cervical cancer (11)
Clinical research (44850)
Collaboration (1027)
Company closure (1)
Compensation (376)
Complete response letters (53)
COVID-19 (1156)
CRISPR (51)
C-suite (553)
Cystic fibrosis (88)
Data (3323)
Decentralized trials (2)
Denatured (27)
Depression (84)
Diabetes (250)
Diagnostics (1893)
Digital health (17)
Diversity (9)
Diversity, equity & inclusion (22)
Drug discovery (177)
Drug pricing (200)
Drug shortages (33)
Duchenne muscular dystrophy (140)
Earnings (40952)
Editorial (48)
Employer branding (10)
Employer resources (79)
Events (50960)
Executive appointments (629)
FDA (9443)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (3)
Frontotemporal dementia (5)
Funding (664)
Gene editing (93)
Generative AI (31)
Gene therapy (274)
GLP-1 (829)
Government (2022)
Grass and pollen (4)
Guidances (205)
Healthcare (5923)
HIV (30)
Huntington's disease (24)
IgA nephropathy (62)
Immunology and inflammation (170)
Immuno-oncology (36)
Indications (71)
Infectious disease (1295)
Inflammatory bowel disease (120)
Inflation Reduction Act (12)
Influenza (49)
Intellectual property (138)
Interviews (118)
IPO (7430)
IRA (54)
Job creations (2444)
Job search strategy (654)
JPM (53)
Kidney cancer (10)
Labor market (63)
Layoffs (344)
Leadership (28)
Legal (4157)
Liver cancer (37)
Longevity (8)
Lung cancer (334)
Lymphoma (209)
Machine learning (21)
Management (31)
Manufacturing (535)
MASH (107)
Medical device (2004)
Medtech (2012)
Mergers & acquisitions (11773)
Metabolic disorders (895)
Multiple sclerosis (103)
NASH (20)
Neurodegenerative disease (161)
Neuropsychiatric disorders (73)
Neuroscience (1528)
Neurotech (1)
NextGen: Class of 2026 (2363)
Non-profit (917)
Now hiring (47)
Obesity (523)
Opinion (232)
Ovarian cancer (67)
Pain (148)
Pancreatic cancer (97)
Parkinson's disease (155)
Partnered (18)
Patents (283)
Patient recruitment (253)
Peanut (19)
People (34514)
Pharmaceutical (76)
Pharmacy benefit managers (33)
Phase 1 (14127)
Phase 2 (18918)
Phase 3 (15205)
Pipeline (2973)
Policy (236)
Postmarket research (1619)
Preclinical (4939)
Press Release (29)
Prostate cancer (133)
Psychedelics (28)
Radiopharmaceuticals (182)
Rare diseases (533)
Real estate (3204)
Recruiting (34)
Regulatory (13789)
Reports (25)
Research institute (836)
Resumes & cover letters (141)
Rett syndrome (6)
RNA editing (12)
RSV (43)
Schizophrenia (120)
Series A (120)
Series B (88)
Service/supplier (7)
Sickle cell disease (66)
Special edition (21)
Spinal muscular atrophy (119)
Sponsored (18)
Startups (2042)
State (2)
Stomach cancer (12)
Supply chain (76)
Tariffs (94)
The Weekly (84)
Vaccines (415)
Venture capital (69)
Weight loss (382)
Women's health (41)
Worklife (9)
Date
Last 7 days (290)
Last 30 days (1031)
Last 365 days (15201)
2026 (1754)
2025 (15480)
2024 (17668)
2023 (19637)
2022 (25866)
2021 (26639)
2020 (24871)
2019 (20057)
2018 (15587)
2017 (17253)
2016 (16203)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (414)
Alabama (41)
Alaska (1)
Arizona (93)
Arkansas (8)
Asia (25950)
Australia (3336)
California (4826)
Canada (1836)
China (759)
Colorado (199)
Connecticut (200)
Delaware (183)
Europe (53535)
Florida (847)
Georgia (98)
Hawaii (2)
Idaho (18)
Illinois (446)
India (53)
Indiana (295)
Iowa (5)
Japan (328)
Kansas (83)
Kentucky (29)
Louisiana (7)
Maine (4)
Maryland (601)
Massachusetts (3888)
Michigan (68)
Minnesota (244)
Mississippi (3)
Missouri (42)
Montana (12)
Nebraska (14)
Nevada (35)
New Hampshire (10)
New Jersey (1874)
New Mexico (21)
New York (1323)
North Carolina (805)
North Dakota (2)
Northern California (2259)
Ohio (131)
Oklahoma (8)
Oregon (23)
Pennsylvania (1068)
Puerto Rico (21)
Rhode Island (28)
South America (616)
South Carolina (11)
Southern California (2047)
Tennessee (65)
Texas (657)
United States (18319)
Utah (95)
Virginia (178)
Washington D.C. (60)
Washington State (377)
West Virginia (1)
Wisconsin (51)
Wyoming (1)
345,978 Results for "recce pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
As mental health patients turn to AI chatbots, how can pharma lead the way?
A new report by Bryter released today reveals where pharma can lead as patients turn to (and question) AI tools for mental health.
February 5, 2026
·
1 min read
Drug pricing
Despite MFN Deals, Drug Pricing Will Dog Pharma Into 2026
Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller biotechs continue to hang in limbo.
January 6, 2026
·
5 min read
·
Annalee Armstrong
Mergers & acquisitions
At JPM26, Policy and Politics Will Loom Large for Pharma as Biotech Sees the Sun
Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a break after a few tough years.
January 9, 2026
·
4 min read
·
Annalee Armstrong
Japan
Japanese Pharmas Looking Beyond Borders for M&A to US, EU
Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.
December 10, 2025
·
7 min read
·
Dan Samorodnitsky
Editorial
GSK CEO Emma Walmsley’s Departure Reseals Pharma’s Glass Ceiling
After Emma Walmsley steps down as GSK CEO in January, Vertex Pharma’s Reshma Kewalramani will be the sole female CEO at a top-20 pharma company. Still, there are many prominent women in pharma that could someday break through again.
September 29, 2025
·
1 min read
·
Annalee Armstrong
Drug pricing
UK Agrees To Boost Drug Spending by 25% To Avoid US Pharma Tariffs
U.K.-based pharmas will not face tariffs as long as Donald Trump is president, according to the agreement.
December 1, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives
February 27, 2025
·
3 min read
Press Releases
Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections
April 23, 2025
·
5 min read
Mergers & acquisitions
Five Assets Given Away by Big Pharma That Ultimately Got Bought for Billions
Drug candidates don’t usually move among Big Pharma, but these five biotechs helped facilitate such hand-offs, scooping up assets from one pharma on the cheap before being bought out for billions by another.
November 19, 2025
·
9 min read
·
Tristan Manalac
Mergers & acquisitions
5 SMID-Cap Pharmas Poised for M&A Action
Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the small- to mid-cap pharmas best prepared to bolster their pipelines with a buyout.
October 29, 2025
·
7 min read
·
Annalee Armstrong
1 of 34,598
Next
